42:5 797-802 (1996) clinical Chemistry Nearly everyone in the clinical laboratory profession has at one time or another solved a problem by developing and (or) using new technology.
The history of clinical laboratory science is replete with examples of problems being conquered through new technologies [1] [2] [3] [4] . Implementing these service improvements was a fairly simple matter in years past. All it took was the perception that the benefits outweighed the risks. Often this perception was correct: A new test provided more accurate diagnoses, a new instrument enhanced productivity, a marker for rejection improved transplant survival, more tests led to increased reimbursement, and so on. The unique mix of challenges confronting clinical laboratorians today causes wonder about whether advancing technolo-gies will continue to provide similar benefits as before. Implementation of new technology in today's marketplace is significantly influenced by two other topics of the Forum: 1) Regulatory pressures affect the development of new technology as never before. Statutes such as the complexity level designation described in the 1988 Clinical Laboratory Improvement Amendments (CLIA) [5] steer diagnostics manufacturers to design features into their products that ensure a "moderate complexity"
or "waived" classification and the personnel flexibility for their customer that results [6] . A backlog in the Food and Drug Administration (FDA) in vitro diagnostic device approval process affects the diagnostics industry in the US with unaccustomed delays, meaning new developments are not able to reach the US market in the same timely manner as in the past [7] . Some of these companies have therefore decided to launch their new products in other countries [8] .
2) Financial pressures exacerbate the burden on manufacturers and make it tougher for the end-user to take advantage of the new technologies.
Fierce economic constraints on all of healthcare apply equally to laboratories [9] . These fiscal factors cannot be escaped and are generating various trends in response that affect healthcare in general [10] and laboratories in particular [11] .
Other significant challenges, such as ever-increasing physician expectations and the need to enhance the information content of laboratory data, intensify pressure on clinical laboratories. Will to patient care in some fresh ways and will, through development and utilization of new technology, maintain service improvement that has so long characterized our field. Table 1 catalogs some of the main customers of clinical laboratories and a simplified list of their expectations. Physicians and other providers are our primary clients. The reasons why they order our services haven't changed very much over the years and include case-finding in individuals, monitoring a patient's condition, establishing a prognosis, and following therapy. Other less justified but real explanations include their own innate curiosity, defensiveness, and habit, along with a "placebo effect" whereby the patient may feel better if testing is done. Whatever the reason, and almost no matter what the test, providers want the result quickly. The laboratory industry has, of course, fueled this aspiration by providing rapid turnaround for many procedures, which physicians then come to expect from most laboratory services. Physicians also count on laboratories to never make mistakes, at least not ones that affect the medical usefulness of the result. Laboratory professionals need not be troubled over this daunting challenge, however, as long as they remember that perfect laboratory tests do not exist. We should strive to satisfy these provider expectations, but also be vigilant in our educational efforts concerning such subjects as the reality of overlap between healthy and diseased populations and the effect of prevalence of disease on the predictive value of a positive test result in case-finding and screening situations. Because of the paramount position of healthcare providers to laboratories, it is worthwhile to stop at this point and review just what they require from the clinical laboratory.
TASKS EXPECTED OF CLINICAL LABORATORIES TODAY
A feasible list appears in Table 2 . Perhaps foremost, laboratories must provide trustworthiness.
If trust between the laboratory and physician breaks down, a great deal of effort will need to be expended. Maintaining trust from your provider-customers is a lot cheaper than trying to regain or establish it. Physicians will convey lack of trust to patients, their families, and hospital administrators. [13] , among others, argue that quality standards for laboratory tests should be based on within-subject biological variation.
They also point out the advantages of having the lowest possible imprecision, even if biological variation goals have been met. Westgard et al. [14] further demonstrate that generally accepted standards for an analyte as familiar as cholesterol are not adequate to meet the quality goals we think we are meeting. Koenig reinforced the importance to the physician of consistent results [15] .
Taylor stressed this idea that analytical precision has a profound impact on the usefulness of chemical measurements in his landmark book [16] . Fig. 1 illustrates how the precision of an assay affects its utility. A precise method has a far better chance of being accurate than an imprecise method; even somewhat biased methods will still be accurate most of the time if they are precise. limit what services a clinician will utilize, and how many. Patients also apply pressure; they are better informed than ever and are no longer content to wait for action from the clinician (who often used laboratory delays as the excuse for tarrying). These time, cost, and patient pressures mean that physicians increasingly rely on single laboratory results, whereas in the past, multitest profiles, follow-up testing, and confirmatory investigation were common. Hence, the methods laboratorians use today to produce these valuable pieces of data must be exquisitely valid to fit the manner in As clinical laboratories remain competitive and select strategies that maintain their role in healthcare, they will find that they are increasingly dependent upon new technologies supplied by diagnostics companies. These tests, devices, and instrument systems must be selected, evaluated, and implemented in such a way as to ensure satisfaction from all the customers of the laboratory.
The variety of four-, five-, and six-part schemes for conducting these evaluations described in recent years [17] [18] [19] gives us a place to start. Perhaps the summary by Fraser [19] of The mistaken assumption is that a new device can be unpacked, originated, operated according to the manufacturer's directions, and can turn out patient-reportable data all on the same day, and that is the end of method evaluation.
Administrators may love us-for a while, at least-but we deceive them and belittle ourselves. We should not succumb to the notion that we are in a commodity business, which is the image we project if we utilize laboratory tests "right out of the box" as if they were packets of ketchup at a fast food restaurant or motor oil from an auto supply shop. As important as these commodities are, we must realize that we are in the information business, providing information about patients that will affect their lives. As stated above, accurate evaluation and implementation of methods is more crucial than ever. We must reach our conclusions about implementing methods on the basis of the facts, collected in a series of method evaluation experiments. These experiments take some time and use up some reagents and (or) other resources, but this expenditure is a necessary and valuable part of our responsibility.
2) A new method willbeacceptable for use once the experiments are done and the data are collected. If the device is working in accordance with manufacturer's guidelines, creditable-looking data are being produced, the sales representative continues to be friendly and helpful, and we selected the method to begin with, it must be acceptable, right? Nothing is further from the truth! What makes the data creditable?
How do we decide that a method/device/instrument is acceptable? The place to start is by establishing a goal or analytical target before commencing any experiments.
Then actual data are collected, and these data are used to estimate the analytical errors, which are then compared with the allowable error goal. If the actual errors are smaller than the target or allowable error, they are acceptable and the method is acceptable; if the errors are equal to or larger than the target, they are unacceptable and the method must be improved or rejected.
This approach is simple and logical, but it is distressing how often the fundamental step of establishing a goal is bypassed in evaluating methods because of the misguided assumption that collecting experimental data is the most important task, and quickly getting on with conducting experiments is the most cost-effective way to complete a method evaluation task. Comparison-of-methods experiments are often summarized only with the correlation coefficient of the data, where a high (i.e., close to 1.00) value is used to imply equivalency between the two methods (i.e., accuracy). In actual fact, the correlation coefficient does not relay any information about whether one method agrees with another method, only the degree to which the data from the two methods are associated with each other.
Careful thinking about this situation should make one realize that two methods measuring the same analyte should be highly associated (or "correlated") with each other. That fact is almost a given before the experiments are begun; what is desired is to know how accurate the new method is compared with the old method. A high correlation coefficient is not informative about the question we need to answer; for that inquiry, the slope and y-intercept from regression of the data are necessary. In reality, the correlation coefficient is primarily a function of the range of the data [24] ; widening the range will cause the correlation coefficient to approach 1.0 regardless of whether the new method is accurate compared with the old method, which will confuse both the investigator and the reader.
A similar mistake is made in regard to the t-value. A t-value indicating a statistically insignificant bias does not prove accuracy; neither does a statistically significant t-value show inaccuracy. The t-value can be very misleading by itself, being the ratio of bias to imprecision [22] ; other statistics are of much greater value in assessing accuracy from method evaluation experiments.
So-use statistics in analytical method evaluation, but use the right ones and know what information these statistics provide.
5) Conclusions about the acceptability of a method being evaluated
are easy-just accept themethod givingthe "most bang for the buck. Clearly, clinical laboratorians must join the rest of healthcare in efforts to reduce cost. But accepting methods should not be based solely on the financial picture; they are not easy decisions to simply accept the low bid. Rather, these conclusions must be made objectively, on the basis of data and other information collected during the method selection and evaluation process. A recent study [25] gives an example of following the key steps to analytical evaluation correctly. If these five common mistakes of analytical method evaluation are avoided, correct assessment of the technical efficacy of a test can be assured. If a method is shown to provide reproducible and valid analytical results, other steps in the assessment of the test can proceed.
The second phase of new test evaluation is determination of the reference range. Again, several resources are available to guide this process, including a guideline from the NCCLS [26] . Fraser [19] terms this Phase 2 trial the "overlap investigation" because he includes the additional step of comparing the values found in healthy individuals with those found in samples from diseased individuals.
That experiment is actually more a part of the third phase of evaluation, which is clinical investigation or measure of the diagnostic accuracy of the new procedure.
The degree of overlap between the distribution of values relating to the population with a given disease and the values from the healthy or reference population is essential data to assess the quality of information produced by measuring the analyte. The smaller the overlapping area, the greater the diagnostic accuracy available from the test. This clinical investigation is measurable by determining the diagnostic sensitivity and specificity of the test, although reporting only one value for these quantities is deceptive since an analyte can have different values of diagnostic sensitivity and specificity simply by changing the cutoff or discriminant value. A more complete, graphical alternative to presenting this information is the use of receiver-operating characteristic (ROC) curves. ROC curve analysis is a powerful tool in this phase of the evaluation of a laboratory procedure whenever the test is applied to discriminate between two alternative states of health. A review [27] and several examples of their application [28, 29] provide assistance in the use of ROC curves. The NCCLS also has a guideline [30] in this aspect of laboratory test evaluation. ROC curve analysis is only as good as the patient population studied, however, and the skill with which clinical judgments used to classify these patients have been made.
As an analyte becomes established and is applied by more than just the initial investigators, estimates of its diagnostic accuracy and clinical value may differ among various studies. Decisions about the implementation of such a test then depend upon the fourth phase in evaluation, the outcome investigation. This phase tries to answer the question of whether individuals subject to the procedure or test gain an advantage vs if they had not undergone the procedure. One way to make sense out of the various potentially conflicting studies is to statistically combine the results of previous research through metaanalysis. General guidelines for this approach [31] and an application of metaanalysis to clinical chemistry [32] have been provided. This fourth phase of the evaluation may also be said to address the impact of the test in the care and management of patients by physicians. If the result of the test does not add to or measurably influence the outcome of the patient, don't do the test.
The final phase in the evaluation of a test is utility investigation or cost-benefit analysis. These studies are difficult but bear more importance in this era of cost containment. The cost to the individual patient relative to the outcome, and the cost to society at large vs the cost if the test wasn't performed, need to be assessed. This analysis can also be valuable for long-standing assays as clinical laboratory professionals serve as consultants on utilization of laboratory services. The first three phases of these trials should ideally be performed before a new procedure is introduced into routine use. In fact, the FDA approval process has incorporated many of these steps into the application for marketing authorization, which will ensure that at least some data pertinent to each aspect will be available from the inception. Phases 4 and 5 should occur early during the establishment of the test as laboratory professionals (ideally different from those who originated the test) assess the test's efficacy in the marketplace.
These studies must be published in some fashion and made widely available so all may benefit and little work will be needlessly repeated.
Who should perform these trials? Clinical laboratorians in all branches of the profession will continue to produce a large amount of the data and experience that will answer the questions asked in these trials. Indeed, the Graylyn Conference defined competency characteristics for clinical pathologists [33] ,in which "select, evaluate, and apply laboratory instruments and procedures..." is the second of five on the list. McDonald and Smith/JO] quite correctly extended this skill requirement to clinical laboratory Ph.D. scientists, as well. Appropriate clinical laboratories must shoulder an increasing share of the development load, which includes performance of these evaluative exercises. The same is true of the diagnostics manufacturers who stand to benefit financially from new technologies.
Perhaps the best scenario will see manufacturers and clinical laboratorians working more closely together to conduct the required experiments.
Manufacturers can supply some of the resources that are now in short supply, while clinical laboratorians of hospitals and other healthcare institutions can supply practical expertise, samples from patients, and professional oversight of the evaluative protocols, data, and the conclusions.
Beyond working with each other, these two groups can also benefit from the cooperation of motivated clinicians, especially in regards to phases 3, 4, and 5. 
AND ECONOMIC CONSTRAINTS
Decisions to implement new technologies are more complex than in the past, but can be made with confidence if they are justified with appropriate data and based on these data rather than on some extraneous, impulsive, prejudiced motive. Interested clinicians can be used effectively to assist in correctly assessing the new technol-and implementing new technologies ogy, particularly in phases 3-5 of the evaluation. These and other healthcare colleagues can also be of help to justify whatever purchase is necessary to administration.
Scarce resources must be spent wisely, and support from clinical staff adds credence to what laboratorians request. Often a few dollars spent in the laboratory can save hundreds elsewhere in the institution.
Justifying
and implementing new technology these days demands that the clinical laboratory develop trust. With a dogged determination to continuously improve in the effort to meet the customer's needs, laboratories will project the image of not being technology driven, but rather using technology to better satisfy the customer. This perspective should characterize the entire institution; perhaps the laboratory can be the place where this approach is championed.
The entire laboratory staff will ideally contribute to this attitude; one way to foster that outcome is through empowerment of the personnel. Empowerment energizes the people closest to patient care delivery; these staff can thus best improve processes and enhance cost-effective delivery of services. A dynamic, straightforward book [34] makes this point in a most enjoyable way. This book should be required reading for anyone engaged in patient care today.
Some comments at the 1995 Forum made in reaction to this presentation indicated that it was too idealistic. Perhaps they are right. But each of us cannot change the situation we are in or alter the challenges we face very much, in spite of how hard we might try. The only factor over which we can exercise some choice is our attitude or response to these situations.
With a positive attitude and a clear focus regarding our objectives, we can continue choosing, evaluating, and implementing new technologies to our satisfaction and to the betterment of our contributions to healthcare.
